Definium Therapeutics, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Definium Therapeutics announced FDA Breakthrough Therapy designation for DT120 (lysergide) orally disintegrating tablet in major depressive disorder (MDD), following positive Phase 3 Emerge study results showing 8.1-point placebo-adjusted improvement in MADRS score at Week 6 (p=0.0001). This is the second Breakthrough designation for DT120, following an earlier designation for generalized anxiety disorder (GAD). No financial figures, deal terms, or share issuances are disclosed in this announcement.
Why this rating
Breakthrough designation meaningfully accelerates regulatory pathway for $488M market-cap biotech; validates clinical efficacy and expands addressable market from GAD to MDD (21M U.S. patients annually). Regulatory de-risking is material for late-stage developer with single lead program.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.